Wire · opportunities
Cardiff Oncology settles Nerviano dispute, amends license
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 15 September 2026 · Fusion42 review
Cardiff Oncology and Nerviano Medical Sciences resolved their litigation over the onvansertib exclusive license with no payments exchanged, and amended the license to tighten exclusivity, adjust royalties and fees, and enhance joint governance in advance of Cardiff's planned Phase 3 clinical program.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
The legal hurdles blocking your drug candidate have cleared and exclusivity terms now control competition tightly. Cardiff's deal shows how resolving license fights sharpens market access and funding for late-stage clinical drug developers.
◆ Coverage
1 source · 14 Sep 2026
◆ Related on Wire
◆ Topics